Kiniksa Pharmaceuticals International KNSA
NASDAQ KNSA
$74.00 -0.61 (-0.82%)
As of: Oct 1, 2026 · 9:45 AM EDT

Kiniksa Pharmaceuticals International (KNSA) Current Deferred Revenue (2022 - 2024)

Updated

Kiniksa Pharmaceuticals International (KNSA) posted Current Deferred Revenue of $12,000 for Q2 2024, down 99.7% from $4.67 million a year earlier and down 92.3% from the prior quarter.

Analysis

Kiniksa Pharmaceuticals International (KNSA) Current Deferred Revenue (2022 - 2024) Analysis & Trends

At the end of FY2023, Kiniksa Pharmaceuticals International's Current Deferred Revenue came in at $307,000.

  • According to Business Quant data, Current Deferred Revenue for the three prior quarters was $156,000 (Q1 2024), $307,000 (Q4 2023) and $2.56 million (Q3 2023).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Kiniksa Pharmaceuticals International 11.64 Bn 10.38 Bn 220.03 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2024 12,000.00
Mar 31, 2024 156,000.00
Dec 31, 2023 307,000.00
Sep 30, 2023 2.56 Mn
Jun 30, 2023 4.67 Mn
Mar 31, 2023 6.50 Mn
Sep 30, 2022 12.09 Mn
API Access

Kiniksa Pharmaceuticals International Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=KNSA&period=max&api_key=YOUR_API_KEY